This article first appeared on GuruFocus.
After a Rome court ruled that Netflix (NFLX, Financials) raised subscription prices from 2017 to 2024 in violation of consumer protection laws, the company is at greater legal risk in Italy.
The court said that Netflix's contract terms didn't clearly explain why those prices went up. The decision could mean that millions of current and former users get their money back.
The court also told Netflix to lower prices for users who were affected. The price of a premium plan could go down from 19.99 to 11.99, and the price of a standard plan could go down from 13.99 to 9.99.
Lawyers for the consumer group said premium users who had been paying since 2017 could get back up to 500. Users of the standard plan could get about 250.
The court also told Netflix to tell affected users, including former subscribers, and to post the decision on its website and in the national press.
Netflix has said that it thinks its terms were in line with Italian law and plans to appeal. The company hasn't responded to the latest order to lower prices.
LATEST POSTS
- 1
Merz says army could be involved in mine-clearing from Hormuz - 2
Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge - 3
New nesting beach for birds at RSPB reserve - 4
CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year - 5
What’s the shadowy organisation taking Gaza Palestinians to South Africa?
Genome study reveals milestone in history of cat domestication
Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
The 25 Most Notable Style Crossroads in History
Students were skipping my astrophysics class to play video games – so I turned the class itself into a video game
Select Your Cherished Fish
The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
The most effective method to Recognize an Excellent Lab Precious stone
NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
Pfizer says patient dies after receiving hemophilia drug in trial












